Sign inJoin waitlistJoin the waitlist

Katherine Kurnit

Assistant Professor, Gynecologic Oncology · Pritzker School of Medicine

Credentials: · · · · · · ·

History

Pritzker School of Medicine
Present
Pritzker School of Medicine · University of Chicago Medical Center
Present
Pritzker School of Medicine · University of Chicago Medical Center
Present

Obstetrics and Gynecology
University of California (San Diego) Medical Center
2019–2023
Gynecologic Oncology
University of Texas M D Anderson Cancer Center
2016–2019
Washington University School of Medicine
2007–2011

Research

CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence
Modern Pathology · 2017 · First of 7 authors · 265 citations
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment
Review · Obstetrics and Gynecology · 2021 · First of 3 authors · 252 citations
Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association
Modern Pathology · 2018 · 117 citations

Shannon Westin
10 papers
Russell Broaddus
9 papers
Gini Fleming
8 papers
Ernst Lengyel
6 papers
Diane Yamada
5 papers
Gretchen Glaser
5 papers
Nita Lee
5 papers · 1 as a fellow
Gordon Mills
4 papers
Ricardo Lastra
4 papers
Andrea Mariani
3 papers
Pamela Soliman
3 papers · 2 as a resident
RC
Robert Coleman
3 papers

Clinical trials

Signatera Assessment in Early-Stage Endometrial Cancer
Site PI · Not yet recruiting
Natera, Inc.
2026–2034
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2023–2027
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027